Praziquantel
(praz'' i kwon' tel).
4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-. 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino-[2,1-a]isoquinolin-4-one [55268-74-1]. » Praziquantel contains not less than 98.5 percent and not more than 101.0 percent of C19H24N2O2, calculated on the dried basis.
Packaging and storage
Preserve in well-closed, light-resistant containers.
USP Reference standards 11
USP Praziquantel Related Compound A RS
2-Benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino [2,1-a]isoquinolin-4-one. C19H18N2O2 306.37
USP Praziquantel Related Compound B RS
2-(Cyclohexylcarbonyl)-2,3,6,7-tetrahydro-4H-pyrazino [2,1-a]isoquinolin-4-one. C19H22N2O2 310.40
USP Praziquantel Related Compound C RS
2-(N-Formylhexahydrohippuroyl-1,2,3,4-tetrahydroisoquinolin-1-one. C19H22N2O4 342.39
Identification,
Infrared Absorption 197K.
Melting range 741:
between 136 and 142.
Loss on drying 731
Dry it in vacuum at a pressure not exceeding 5 mm of mercury at 50 over phosphorus pentoxide for 2 hours: it loses not more than 0.5% of its weight.
Residue on ignition 281:
not more than 0.1%.
Phosphate
Cupric sulfate solution
Dissolve 250 mg of cupric sulfate and 4.5 g of ammonium acetate in sufficient 2 N acetic acid to obtain 100 mL of solution.
4-Amino-3-hydroxy-1-naphthalenesulfonic acid solution
Grind in a mortar 5 g of sodium sulfite, 94.3 g of sodium metabisulfite, and 700 mg of 4-amino-3-hydroxy-1-naphthalenesulfonic acid. Dissolve 1.5 g of this mixture in 10 mL of water, heating gently if necessary. Use this solution only when freshly prepared.
Standard solution
Dissolve 143.3 mg of dried monobasic potassium phosphate in water to make 1000 mL of solution. Transfer 5.0 mL of this solution to a 100-mL volumetric flask, dilute with water to volume, and mix. This solution contains the equivalent of 5 µg of phosphate (PO4) in each mL.
Test solution
Add 30 mL of water to 500 mg of specimen, and heat to boiling. Allow to cool, and filter, collecting the filtrate in a 50-mL volumetric flask. Wash the filter with water, collecting the washings in the volumetric flask, dilute with water to volume, and mix.
Procedure
Treat 10 mL of Test solution and 10 mL of Standard solution as follows. To each add 5 mL of Cupric sulfate solution, 2 mL of ammonium molybdate solution (3 in 100), 1 mL of 4-Amino-3-hydroxy-1-naphthalenesulfonic acid solution, and 1 mL of perchloric acid solution (3 in 100), mix, and allow to stand for 15 minutes: the Test solution does not have a blue color that is darker than that of the Standard solution (0.05%).
Heavy metals, Method II 231:
0.002%.
Related compounds
Mobile phase and Chromatographic system
Prepare as directed in the Assay.
Standard preparation
Dissolve accurately weighed quantities of USP Praziquantel Related Compound A RS, USP Praziquantel Related Compound B RS, and USP Praziquantel Related Compound C RS in Mobile phase to obtain a single solution having known concentrations of about 0.04 mg of each per mL.
Test preparation
Transfer about 200 mg of Praziquantel, accurately weighed, to a 10-mL volumetric flask, dissolve in and dilute with Mobile phase to volume, and mix.
Procedure
Separately inject equal volumes (about 10 µL) of the Standard preparation and the Test preparation into the chromatograph, record the chromatograms, and measure the responses for the peaks. The relative retention times are about 0.8 for praziquantel related compound A, 1.0 for praziquantel, 1.8 for praziquantel related compound B, and 2.1 for praziquantel related compound C. Calculate, in turn, the percentages of 2-benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one (praziquantel related compound A), 2-(cyclohexylcarbonyl)-2,3,6,7-tetrahydro-4H-pyrazino[2,1-a]isoquinolin-4-one (praziquantel related compound B), and 2-(N-formylhexahydrohippuroyl)-1,2,3,4-tetrahydroisoquinolin-1-one (praziquantel related compound C) in the portion of Praziquantel taken by the formula:
1000(C/W)(rU / rS)
in which C is the concentration, in mg per mL, of the respective USP Reference Standard taken to prepare the Standard preparation; W is the weight, in mg, of Praziquantel taken to prepare the Test preparation; and rU and rS are the peak responses at corresponding retention times, obtained from the Test preparation and the Standard preparation, respectively. Not more than 0.2% of each is found.
Assay
Mobile phase
Prepare a suitable degassed mixture of acetonitrile and water (60:40). Make adjustments if necessary (see System Suitability under Chromatography 621).
Standard preparation
Dissolve an accurately weighed quantity of USP Praziquantel RS in Mobile phase, and dilute quantitatively, and stepwise if necessary, with Mobile phase to obtain a solution having a known concentration of about 0.18 mg per mL.
Assay preparation
Transfer about 36 mg of Praziquantel, accurately weighed, to a 20-mL volumetric flask, dissolve in and dilute with Mobile phase to volume, and mix. Transfer 5.0 mL of the solution so obtained to a 50-mL volumetric flask, dilute with Mobile phase to volume, and mix.
Chromatographic system (see Chromatography 621)
The liquid chromatograph is equipped with a 210-nm detector and a 4-mm × 25-cm column that contains 10-µm packing L1. The flow rate is about 1.5 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the tailing factor is not more than 1.5; and the relative standard deviation for replicate injections is not more than 1.0%.
Procedure
Separately inject equal volumes (about 10 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C19H24N2O2 in the portion of Praziquantel taken by the formula:
200C(rU / rS)
in which C is the concentration, in mg per mL, ofUSP Praziquantel RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 4391
Pharmacopeial Forum: Volume No. 28(6) Page 1853
|